Evolus, Inc.
EOLS · XNASCIK 1570562fmd_1YPEGMRVM5FCE82E4V24NDQTXPManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 39 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 35 | 57 | 100 | 149 | 202 | 266 | 297 |
| Cost of revenue | – | 0 | 8 | 18 | 44 | 59 | 65 | 84 | 100 |
| Gross profit | – | 0 | 27 | 38 | 56 | 90 | 138 | 182 | 197 |
| Research and development | 7 | 6 | 4 | 2 | 2 | 5 | 7 | 9 | 10 |
| Selling, general and administrative | – | 29 | 114 | 98 | 112 | 142 | 165 | 198 | 221 |
| Total operating expenses | 12 | 46 | 126 | – | – | – | – | – | – |
| Operating income | (12) | (46) | (99) | (153) | (44) | (65) | (49) | (34) | (33) |
| Interest expense | 0 | 1 | – | – | 1 | 9 | 14 | 19 | 20 |
| Interest and investment income | 0 | 0 | – | – | – | – | – | – | – |
| Other non-operating income (expense) | – | (1) | (8) | (11) | 0 | (0) | 1 | 0 | (1) |
| Income before taxes | (12) | (47) | (105) | (163) | (47) | (74) | (62) | (50) | (51) |
| Income tax expense | (7) | 0 | (15) | 0 | 0 | 0 | 0 | 1 | 1 |
| Net income from continuing operations | (4) | (47) | (90) | (163) | (47) | (74) | (62) | (50) | (52) |
| Net income | (4) | (47) | (90) | (163) | (47) | (74) | (62) | (50) | (52) |